Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the
treatment of psoriasis. A total of approximately 24 subjects will be randomized into 3
cohorts(15mg, 30mg, 60mg), approximately 8 healthy subjects will be enrolled (6 active and 2
placebo) at each dose cohort. This study includes an 28-day Screening Period, a 1-day single
dose and 7-days multiple doses Treatment Period, and an End of Study Visit occurring
approximately 11days (±3 days) after study drug administration.